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Background: Alzheimer’s disease (AD) is the most common form of dementia and patients often have visual
disorders. Mild cognitive impairment (MCI) is characterized by a memory deficit when compared with those of a
similar age and education level which could indicate an earlier onset of AD. The aim of this study is to measure the
changes of the retinal nerve fiber layer (RNFL) thickness of AD and MCI patients in comparison with the normal age
controls.
Methods: The RNFL thickness was assessed using optical coherence tomography (OCT) in patients with MCI,
AD (mild, moderate and severe) and the age matched controls.
Results: The thickness of RNFL in the superior quadrant and total mean values are gradually and significantly
decreased from MCI to severe AD when compared to that in the controls. There is also a significant reduction
of the retinal nerve fiber layer in the inferior quadrant in severe AD patients.
Conclusions: Our data indicate that the retinal nerve fiber layer degeneration is paralleled with dementia
progression. Owing to its non-invasive and cost effective nature, monitoring RNFL thickness may have a value
in assessing disease progression and the efficacy of any treatments.
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Alzheimer’s disease (AD) is the most common form of de-
mentia and is characterized by cognitive deficits including
progressive memory disturbances, aphasia, apraxia and ag-
nosia. AD patients also have visual problems affecting vis-
ual acuity [1], stereopsis, colour vision, spatial contrast
sensitivity and ocular motility [2]. The typical pathological
changes in AD are senile plaques and neurofibrillary tan-
gles in the central nervous system (CNS). Mild cognitive
impairment (MCI) is defined as impairment in cognitive
functions with otherwise normal performance of activities
of daily life [3]. MCI is a broad term that encompasses
several subtypes of cognitive dysfunction. Amnesic MCI* Correspondence: louiselu1964@163.com
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unless otherwise stated.patients may show an early transitional stage development
of AD and have memory impairment, but without demen-
tia [4]. 10% -15% MCI suffers are most likely to progress
to AD per year while 1% to 2% of healthy people are in a
risk developing to AD [5,6].
Optical coherence tomography (OCT) is a well-established
non-invasive examination that can assess the thickness of
retinal nerve fiber layer (RNFL) and is used in various oph-
thalmologic diseases including glaucoma, ocular hyperten-
sion, optic neuropathy and multiple sclerosis [7]. Previous
reports have demonstrated a possible degeneration of the
RNFL in AD [8-15]. For example, a postmortem study by
Hilton et al., found widespread axonal degeneration in the
optic nerves in 8 out of 10 AD sufferers [16]. Sadun’s work
also suggested that the degeneration of ganglion cells were
mainly observed in large M-cell axons [8]. However, other
studies failed to support those findings [17,18], indicating
that methodological differences may be responsible for thoses is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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the present study was to determine with a sophisticated
OCT method whether the thickness of the RNFL is propor-
tionally reduced from MCI patients, mild AD to severe AD
patients compared to that in the age-matched healthy
controls.Methods
After approval from the Ethics committee of Xuanwu
Hospital, Capital Medical University, Beijing, China and
written informed consent was obtained, 26 MCI, 24 mild
AD patients, 24 moderate AD patients, 19 severe AD pa-
tients and 39 age-matched controls were enrolled into
the study. All patients and controls were examined for
visual acuity, refractive error, intraocular pressure (IOP),
anterior and posterior segment biomicroscopy, dilated
fundus examination.
All AD patients were diagnosed by the AD group of
neurologists in the department of Neurology in Xuanwu
Hospital according to the National Institute of Neurologic
and Communicative Disorders and Stroke–Alzheimer’s
Disease and Related Disorders Association (NINCDS-
ADRDA) [19] and the Diagnostic and Statistical Manual
of Mental Disorders (DSM IV) criteria [20].
Each of the MCI patients are diagnosed by three neurol-
ogists in the department of Neurology Xuanwu hospital
according to Petersen criteria [21]. The criteria for con-
trols were: (1) no memory complaints; (2) MMSE scores
above 28. Additional criteria requirements for all study
subjects are: (1) Diopters: spherical −3.00DS ~ +3.00DS,
cylinder −3.00 DC~ + 3.00 DC, anisometropia ≤ 2D;(2)
IOP measured three times < 21 mmHg; Exclusion criteria
was: glaucoma and increased intraocular pressure, retinal
detachment, retinal artery occlusion, optic neuropathy,
ocular trauma or surgery, diabetes mellitus, hypertension,
cerebral infarction and other diseases which may affect
RNFL thickness.
OCT evaluations were done according to the standard
procedures using a STRATUS OCT 3 (Carl Zeiss AG,
Oberkochen, Germany). Near infrared super-luminescent
diode light allows the OCT to generate two dimensionalTable 1 The clinical data of patients with MCI, mild, moderate
MCI MI AD MO AD
(n = 26) (n = 24) (n = 24)
Sex M 12 9 11
F 14 15 13
Age (y) 70.2 ± 6.5 71.3 ± 4.9 70.8 ± 6.1
IOP (mmHg) 16.1 ± 1.3 15.9 ± 2.1 15.1 ± 1.2
VA (logMAR) 0.16 ± 0.08 0.21 ± 0.10 0.33 ± 0.0
MCI: Mild cognitive impairment; AD: Alzheimer’s disease; n: eyes; MI: mild; MO: mod
SE: severe; M: male; F: female; IOP: intraocular pressure; VA: visual acuity.images of the retina. RNFL thickness was circularly
measured around the papilla (optic disc: 3.4 mm) and
repeated three times per quadrant (superior, inferior,
nasal and temporal) and the average of the 12 values
were used for each eye as expressed in μm. The thresh-
old of scanning signal was set to be ≥ 6.
Data are reported as mean ± SD and statistical analysis
was performed with SPSS 16.0 (SPSS Inc, Chicago, IL,
USA). The differences about gender constituent ratio
among controls, MCI, mild AD, moderate AD and se-
vere AD were compared with chi-square test. The differ-
ences about age, IOP, and RNFL thickness among five
groups were evaluated with one-way ANOVA followed
by post hoc comparison with Bonferroni correction to
test the data between groups. A p < 0.05 was considered
to be of statistical significance.Results
There was no statistically significant difference in gen-
der, age and IOP among five groups (P > 0.05) (Table 1).
There was a significant difference between the normal
control group and MCI and 134 mild AD, moderate AD
or severe AD respectively in superior quadrant, inferior
135 quadrant and total mean RNFL thickness (p < 0.05)
but no significant difference in nasal and temporal quad-
rant (p > 0.05). In the superior quadrant and total mean
RNFL, compared with that in the normal control group,
the RNFL thickness of the MCI, mild dementia, moder-
ate dementia and severe dementia group were reduced 139
and there was a statistically significant difference (p < 0.05).
Furthermore, when compared with the MCI group, the
RNFL thicknesses of moderate and severe AD group were
significantly decreased (p < 0.05). There was no significant
difference in RNFL thickness among mild AD, moderate
AD and severe AD groups. In the inferior quadrant, there
are no significant differences (p > 0.05) in the MCI group,
mild AD group and moderate AD group compared with
the control group. In the total mean RNFL, compared with
that in the normal control group, the RNFL thickness of
MCI group, mild AD, moderate AD, severe AD were grad-
ually reduced (p < 0.05) (Table 2). Furthermore, when these, severe AD and control groups (mean ± SD)
SE AD control P
value(n = 19) (n = 39)
9 17 X2 = 0.370 >0.05
10 22
72.1 ± 4.6 69.7 ± 7.8 F = 1.341 >0.05
14.4 ± 1.2 15.9 ± 0.9 F = 2.260 >0.05
1 0.35 ± 0.03 0.06 ± 0.09 F = 3.501 <0.05
erate.
Table 2 RNFL thickness (μm) in patients with MCI, mild, moderate, severe AD and control subjects (mea ± SD)
MCI mild AD moderate AD severe AD control F value
S 115.14 ± 13.51▲ 111.78 ± 11.67▲ 108.89 ± 12.42▲■ 101.56 ± 19.32▲■ 119.10 ± 15.34
2.012*
I 120.23 ± 18.04 115.11 ± 10.56 113.23 ± 16.21 111.41 ± 10.64▲■ 125.67 ± 11.23
5.549**
N 74.80 ± 12.36 69.76 ± 11.64 64.41 ± 15.87 61.12 ± 17.54 79.98 ± 12.87
1.035
T 63.78 ± 13.16 61.17 ± 12.14 60.43 ± 11.87 60.41 ± 10.82 67.34 ± 15.27
1.256
M 95.37 ± 17.11▲ 91.61 ± 10.10▲ 91.68 ± 12.37▲■ 87.13 ± 17.05▲▲■ 100.12 ± 15.01
7.985**
S: superior of Peripapillary RNFL thickness; I: inferior of Peripapillary RNFL thickness; N: nasal of Peripapillary RNFL thickness; T: temporal of Peripapillary RNFL
thickness; M: total mean of RNFL thickness; Compared with the control group:▲P < 0.05,▲▲P < 0.01; comparison to MCI:■P < 0.05 F test: *p < 0.05, **p < 0.001.
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was a falling trend along with the disease progression
(Figure 1).
Discussion
Our data indicated the thickness of RNFL in the super-
ior quadrant and total mean RNFL was gradually de-
creased that with the disease progression from MCI to
severe AD. There was also a reduction of the retinal
nerve fiber layer in inferior quadrant in severe AD
patients.
In line with our data, a previous study measuring peri-
papillary RNFL in AD by OCT showed that a significant
thinning change of the RNFL was found in the superiorFigure 1 RNFL thickness in patients with MCI, mild, moderate,
severe AD and control subjects. Line graph constructed with data
from Table 2 represents the changing trend of mean RNFL thickness
(μm) plus variations in the superior quadrant (s), inferior quadrant (I)
and total mean (TM) along with the disease progression.quadrant in patients with AD compared with control
subjects. There were no significant differences in the in-
ferior, temporal or nasal RNFL thicknesses between the
groups [22]. Our previous study found that the superior
and inferior quadrants nerve fiber layer thickness was
thinning in the AD patients compared with the healthy
controls measured by OCT [23]. Other reports [24,25]
indicated that there is a clear reduction of RNFL thick-
ness, involving all four quadrants in AD and MCI pa-
tients. Our current data suggest that there is the reduction
in retinal nerve fiber layer in superior quadrant selectively
in the early AD. Accompanying with the development of
AD, the degeneration of the retinal nerve fiber layer ap-
pears not only in superior quadrant, but also in inferior
quadrant. The reason for such selective thinning RNFL in
the superior region remains unknown. Anatomically,
axons from the superior retina project via the parietal
lobe portion of the optic radiation to the cuneal gyrus
of the primary visual cortex, whereas axons from the
inferior retina project to the lingual gyrus. In a histo-
pathology study of cortical damage in AD, Armstrong
[26] found a greater density of senile plaques and
neurofibrillary tangles in the cuneal gyrus than in the
lingual gyrus, and suggested that this difference may ex-
plain the predominantly superior RNFL defects in AD.
Several previous reports indicate that visual problems in
AD were attributed to nerve degeneration in the primary
visual cortex [27-29]. However, there have been increasing
evidence that the primary visual pathways (the optic nerve
and retinal degeneration) may also contribute to the visual
disorders. For example, there are publications suggesting
that the optic nerve and retinal degeneration existed in
patients with AD [5,7-9,16]. That is the case in our study
reported here. Accompanying the development of AD, the
degeneration of the retinal nerve fiber layer appears not
only in superior quadrant, but also in inferior quadrant.
However, some of the literature did not support the
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deficits in visual function that are known to occur in de-
mentia of the Alzheimer’s type are not related to optic
nerve head structural anomalies, at least in the earlier
stages of the disease [30]. Kergoat et al. analyzed fundus
images, captured by scanning laser polarimetry, and they
found no differences in the RNFL thickness observed be-
tween AD and healthy subjects [30]. Hence, this warrants
further study to identify the true reason of visual disorders
in AD and also to clarify whether visual disorders are also
due to disorders of visual cortex and/or primary visual
pathways.
Amyloid-beta (Aβ) plaques which is also known as se-
nile plaques have been reported in postmortem retinal
tissue from patients with AD and the mouse model of
AD [31-33]. We found the degree of the retinal nerve
fiber layer degeneration deteriorated gradually along
with AD development which indicates the retinal Gan-
glion Cell (RGC) losses may be correlated with the dur-
ation of AD progression [2]. Interestingly, amyloid
protein has also been shown to be associated with the
degeneration of RGC in a mouse model of glaucoma [34].
Therefore, amyloid accumulation in the retina of AD pa-
tients may result in degeneration of RGC in parallel to
amyloid-related neurodegeneration in the cerebrum.
MCI constitutes a risk factor for AD. The RNFL thick-
ness occurred in MCI patients being found in our study
is striking although this warrants further study. If this is
true, then it would be very valuable for patients to have
general screening with OCT to further support diagnosis
for a possibility to detect the earlier onset of MCI. Ex-
tensive research is being devoted to identifying individ-
uals who are likely to develop AD from MCI [6]. Our
data showing that RNFL thickness in MCI is reduced
may be further evidence indicating MCI progression in
patients while a follow-up study is needed to explore
how the degree and duration of the RNFL relates to the
progression from MCI to AD. However, cautions must
be taken due to the following reasons: 1) This is a pure
observational cohort study not a trial. Large sample size
is needed to further verify our current findings; 2) Peter-
sen criteria was used to define MCI without further bio-
markers or even evidence from PET imaging; 3) A time
not spectral domain OCT was used and hence lower
resolution images can be problematic for data accuracy.
Nevertheless, our data reported here may guide neurolo-
gists to consider OCT to be additional tool for better
diagnosis and/or treatment monitoring of dementia pa-
tients although it is very plausible to be used to clarify
the severity of dementia.
Conclusions
OCT is a safe and non-invasive method which has been
used to assess retinal degeneration in various ophthalmologicand neurological disorders. From our experience and the
data reported here, it could be suggested that OCT can be
used to improve MCI diagnosis in individuals clinically af-
fected by subtle memory disturbances and to monitor the
progression of Alzheimer’s disease and evaluate effectiveness
of any treatments.
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